Diffuse Large B-cell Lymphoma Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | AbbVie, Genmab, Merck

The Diffuse Large B-cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Diffuse Large B-cell Lymphoma Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Diffuse Large B-cell Lymphoma Market.

Some of the key takeaways from the Diffuse Large B-cell Lymphoma Pipeline Report:

• Companies across the globe are diligently working toward developing novel Diffuse Large B-cell Lymphoma treatment therapies with a considerable amount of success over the years. 
• Diffuse Large B-cell Lymphoma companies working in the treatment market are Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd., Biomea Fusion Inc., Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutica, IMV Inc., Seagen Inc., Zai Lab, Genentech, AbbVie and Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, Roche and Biogen, Autolus Therapeutics, and others, are developing therapies for the Diffuse Large B-cell Lymphoma treatment 

• Emerging Diffuse Large B-cell Lymphoma therapies in the different phases of clinical trials are- UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut S, Brentuximabvedotin, Odronextamab, Mosunetuzumab, Epcoritamab, Zilovertamab vedotin, Glofitamab, Plamotamab, Enzastaurin (DB102), Mivavotinib, LUNSUMIO (mosunetuzumab), Obe-cel, and others are expected to have a significant impact on the Diffuse Large B-cell Lymphoma market in the coming years.   
• In July 2023, Epcoritamab-bysp (Tepkinly) monotherapy in adult patients with relapsed/refractory DLBCL following two or more lines of systemic therapy was recommended for conditional marketing authorization by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP).
• In July 2023, The bispecific antibody (bsAb) glofitamab, sold under the brand name Columvi by Roche, has been given conditional marketing approval by the European Commission (EC) for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL) that has relapsed or become resistant to two or more lines of systemic therapy.
• In April 2023, the FDA granted approval for Polivy (polatuzumab vedotin-piiq) in conjunction with Rituxan (rituximab), cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL), who possess an International Prognostic Index (IPI) score of two or higher.
• In August 2020, In participants with relapsed or refractory DLBCL (R/R DLBCL), Seagen Inc. started a randomised, double-blind, placebo-controlled, multicenter, Phase III investigation of lenalidomide and rituximab in combination with either Brentuximab Vedotin or a placebo.

Diffuse Large B-cell Lymphoma Overview

Non-Hodgkin lymphoma (NHL) includes diffuse large B cell lymphoma (DLBCL). NHL is a lymphatic system cancer.It manifests when the body produces B cells that are aberrant. These white blood cells, called lymphocytes, are a type that often aid in the fight against infections.

Get a Free Sample PDF Report to know more about Diffuse Large B-cell Lymphoma Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-pipeline-insight

Emerging Diffuse Large B-cell Lymphoma Drugs Under Different Phases of Clinical Development Include:

• UBX-303: Ubix Therapeutics
• OPB-111077: Otsuka Pharmaceutical Co., Ltd.
• BMF-219: Biomea Fusion Inc.
• AUTO3: Autolus Limited
• Abexinostat: Xynomic Pharmaceuticals, Inc.
• Poseltinib: Hanmi Pharmaceutica
• Maveropepimut S: IMV Inc.
• Brentuximabvedotin: Seagen Inc.
• Odronextamab: Zai Lab
• Mosunetuzumab: Genentech
• Epcoritamab: AbbVie and Genmab
• Zilovertamab vedotin: Merck
• Glofitamab: Roche
• Plamotamab: Xencor and Janssen
• Enzastaurin (DB102): Denovo Biopharma
• Mivavotinib: Calithera Biosciences
• LUNSUMIO (mosunetuzumab): Roche and Biogen
• Obe-cel: Autolus Therapeutics

Diffuse Large B-cell Lymphoma Route of Administration

Diffuse Large B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Diffuse Large B-cell Lymphoma Molecule Type

Diffuse Large B-cell Lymphoma Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Diffuse Large B-cell Lymphoma Pipeline Therapeutics Assessment

• Diffuse Large B-cell Lymphoma Assessment by Product Type
• Diffuse Large B-cell Lymphoma By Stage and Product Type
• Diffuse Large B-cell Lymphoma Assessment by Route of Administration
• Diffuse Large B-cell Lymphoma By Stage and Route of Administration
• Diffuse Large B-cell Lymphoma Assessment by Molecule Type
• Diffuse Large B-cell Lymphoma by Stage and Molecule Type

DelveInsight’s Diffuse Large B-cell Lymphoma Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Diffuse Large B-cell Lymphoma product details are provided in the report. Download the Diffuse Large B-cell Lymphoma pipeline report to learn more about the emerging Diffuse Large B-cell Lymphoma therapies

Some of the key companies in the Diffuse Large B-cell Lymphoma Therapeutics Market include:

Key companies developing therapies for Diffuse Large B-cell Lymphoma are – AbbVie, Genmab, Merck, Xencor, Janssen, Denovo Biopharma, Calithera Biosciences, IMV, Roche, Biogen, Autolus Therapeutics, Allogene Therapeutics, Novartis, Miltenyi Biomedicine, Regeneron Pharmaceuticals, Debiopharm, Seagen, Takeda, Gilead Sciences, AstraZeneca, and others.

Diffuse Large B-cell Lymphoma Pipeline Analysis:

The Diffuse Large B-cell Lymphoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Diffuse Large B-cell Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Diffuse Large B-cell Lymphoma Treatment.
• Diffuse Large B-cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Diffuse Large B-cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Diffuse Large B-cell Lymphoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Diffuse Large B-cell Lymphoma drugs and therapies

Diffuse Large B-cell Lymphoma Pipeline Market Drivers

• Increasing Prevalence of DLBCL, increased research and development and CAR-T therapies are some of the important factors that are fueling the Diffuse Large B-cell Lymphoma Market.

Diffuse Large B-cell Lymphoma Pipeline Market Barriers

• However, high cost of treatment, aggressive disease biology and geriatric vulnerability and other factors are creating obstacles in the Diffuse Large B-cell Lymphoma Market growth.

Scope of Diffuse Large B-cell Lymphoma Pipeline Drug Insight    

• Coverage: Global
• Key Diffuse Large B-cell Lymphoma Companies: Ubix Therapeutics, Otsuka Pharmaceutical Co., Ltd., Biomea Fusion Inc., Autolus Limited, Xynomic Pharmaceuticals, Inc., Hanmi Pharmaceutica, IMV Inc., Seagen Inc., Zai Lab, Genentech, AbbVie and Genmab, Merck, Roche, Xencor and Janssen, Denovo Biopharma, Calithera Biosciences, Roche and Biogen, Autolus Therapeutics, and others
• Key Diffuse Large B-cell Lymphoma Therapies: UBX-303, OPB-111077, BMF-219, AUTO3, Abexinostat, Poseltinib, Maveropepimut S, Brentuximabvedotin, Odronextamab, Mosunetuzumab, Epcoritamab, Zilovertamab vedotin, Glofitamab, Plamotamab, Enzastaurin (DB102), Mivavotinib, LUNSUMIO (mosunetuzumab), Obe-cel, and others
• Diffuse Large B-cell Lymphoma Therapeutic Assessment: Diffuse Large B-cell Lymphoma current marketed and Diffuse Large B-cell Lymphoma emerging therapies
• Diffuse Large B-cell Lymphoma Market Dynamics: Diffuse Large B-cell Lymphoma market drivers and Diffuse Large B-cell Lymphoma market barriers 

Request for Sample PDF Report for Diffuse Large B-cell Lymphoma Pipeline Assessment and clinical trials

Table of Contents 

1. Diffuse Large B-cell Lymphoma Report Introduction

2. Diffuse Large B-cell Lymphoma Executive Summary

3. Diffuse Large B-cell Lymphoma Overview

4. Diffuse Large B-cell Lymphoma- Analytical Perspective In-depth Commercial Assessment

5. Diffuse Large B-cell Lymphoma Pipeline Therapeutics

6. Diffuse Large B-cell Lymphoma Late Stage Products (Phase II/III)

7. Diffuse Large B-cell Lymphoma Mid Stage Products (Phase II)

8. Diffuse Large B-cell Lymphoma Early Stage Products (Phase I)

9. Diffuse Large B-cell Lymphoma Preclinical Stage Products

10. Diffuse Large B-cell Lymphoma Therapeutics Assessment

11. Diffuse Large B-cell Lymphoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Diffuse Large B-cell Lymphoma Key Companies

14. Diffuse Large B-cell Lymphoma Key Products

15. Diffuse Large B-cell Lymphoma Unmet Needs

16 . Diffuse Large B-cell Lymphoma Market Drivers and Barriers

17. Diffuse Large B-cell Lymphoma Future Perspectives and Conclusion

18. Diffuse Large B-cell Lymphoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services